Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 181 - 200 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
EDSIVO New Drug Application Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Takeaways from our Expert Call on Value-Based Pricing for EDSIVO
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Ravicti Settlement Bodes Well for ACER-001; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Join in our Expert Call on Value-Based Pricing for EDSIVO
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q 2018 Financial Results Reported; EDSIVO Submission Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q18 - EDSIVO NDA Submission Is Right On Schedule
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Financing Completed; Over-Allotment Exercised in Full; Reiterate Buy and Raising Price Target to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Updated EDSIVO - Filing Timeline; Spending Assumptions Revised; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
vEDS Patient Perspective - Buying Time Is the Biggest Hope
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Dial in to Our vEDS Patients'' Perspectives Call on June 28 at 12PM (ET)
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y